Following on from information provided to NICE by the company in August 2018, the appraisal of Bevacizumab for treating recurrent glioblastoma [ID978] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 978 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Discontinued. Following on from information provided to NICE by the company in August 2018, the appraisal of Bevacizumab for treating recurrent glioblastoma [ID978] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 23 January 2017 | Suspended. Please be advised that the Department of Health has asked us to carry out a Single Technology Appraisal of bevacizumab within its marketing authorisation for glioblastoma. However, the company have advised that the pivotal study failed to reach its primary end point and they will not be seeking regulatory approval from the European Medicines Authority for this indication. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual